Low serum concentrations of reboxetine in 2 patients treated with CYP3A4 inducers.
Helland
Arne
A
Spigset
Olav
O
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D052018:Bulimia Nervosa / Q000188:drug therapy; D002220:Carbamazepine / Q000494:pharmacology / Q000627:therapeutic use; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis*; D004336:Drug Antagonism; D004790:Enzyme Induction; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D010634:Phenobarbital / Q000494:pharmacology / Q000627:therapeutic use; D000077593:Reboxetine; D012559:Schizophrenia / Q000188:drug therapy
D018759:Adrenergic Uptake Inhibitors; D000927:Anticonvulsants; D009025:Morpholines; D002220:Carbamazepine; D003577:Cytochrome P-450 Enzyme System; D000077593:Reboxetine; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D010634:Phenobarbital